Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.67 |
| ▸ | HMGCR | P04035 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375334 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL11045543 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL26251491 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL26624468 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL10404839 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL3626347 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL28743000 | 1.00 | PTPN7 (0.67) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL11328048 | 0.98 | PTPN7 (0.64) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL9366458 | 0.98 | PTPN7 (0.63) | PTPN7HMGCRMAPTHSD17B10CYP1A2 | |
| SCHEMBL26624663 | 0.96 | PTPN7 (0.68) | PTPN7HMGCRMAPTHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053661-A | Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053660-A | Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119855607-A | Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application | 太阳雨林(北京)生物医药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213310-A9 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2023213310-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2023-11-09 | — | — | WO | disclosed |
| EP-3762396-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407393-A1 | Medical Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-12-31 | — | — | US | disclosed |
| WO-2019171285-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-09-12 | — | — | WO | disclosed |
| EP-2408793-B1 | METHOD FOR SURFACE FUNCTIONALISATION BY DISUBSTITUTED ALKYNES | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-07-23 | — | — | EP | disclosed |
| WO-2010106246-A1 | METHOD FOR SURFACE FUNCTIONALISATION BY DISUBSTITUTED ALKYNES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-09-23 | — | — | WO | disclosed |
| US-7789934-B2 | Combination of an N-alkyl- or N,N-dialkylpolyhydroxyalkanamide and a metal soap, an alkylenebisfatty amide, or an N-alkylalkanamide; improves both flowability and lubricity, regardless of a presence or absence of a complicated pretreatment step. | KABUSHIKI KAISHA KOBE SEIKO SHO (JP) | 2010-09-07 | — | — | US | disclosed |
| CN-100549146-C | Lubricant for powder metallurgy, mixed powder for powder metallurgy, and method for producing sintered body | KOBE STEEL LTD (JP) | 2009-10-14 | — | — | CN | disclosed |
| US-20070154340-A1 | Lubricant for powder metallurgy, powdery mixture for powder metallurgy, and process for producing sinter | KABUSHIKI KAISHA KOBE SEIKO SHO (JP) | 2007-07-05 | — | — | US | disclosed |
| CN-1910266-A | Lubricant for powder metallurgy, powdery mixture for powder metallurgy, and process for producing sinter | KOBE STEEL LTD (JP) | 2007-02-07 | — | — | CN | disclosed |
| US-7148363-B2 | Process for preparing acrylate compound | TOSOH CORPORATION (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20050148789-A1 | Process for preparing acrylate compound | TOSOH CORPORATION | 2005-07-07 | — | — | US | disclosed |
| US-6833462-B2 | Esterification to get cyclic acrylate compounds; used as raw material for functional polymers, pharmaceuticals, pesticides, semiconductor lithography | TOSOH CORPORATION (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030139613-A1 | Process for preparing acrylate compound | TOSOH CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-4273845-A | Heat-developable photosensitive material | CANON KABUSHIKI KAISHA (JP) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139613-A1 | Process for preparing acrylate compound | AFF1, AFF4, RER1 | PTPN7 3295/4885HMGCR 547/4885MAPT 4606/4885 |
| US-20050148789-A1 | Process for preparing acrylate compound | ACR, AFF4, AFF1 | PTPN7 3437/4885HMGCR 594/4885MAPT 4620/4885 |
| US-20200407393-A1 | Medical Use | ABCB11, SLC10A1, SLC10A2 | PTPN7 2511/4885HMGCR 350/4885MAPT 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.